- Home
- CCII vs AKBA Comparison
CCII vs AKBA Comparison
Compare CCII & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCII | AKBA |
|---|---|---|
| Founded | 2024 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.7M | 343.4M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CCII | AKBA |
|---|---|---|
| Price | $10.32 | $0.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 62.1K | ★ 8.2M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.10 | $0.81 |
| 52 Week High | $10.50 | $3.19 |
Technical Indicators
Market Signals| Indicator | CCII | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 48.10 | 46.52 |
| Support Level | $10.32 | $0.84 |
| Resistance Level | $10.50 | $0.96 |
| Average True Range (ATR) | 0.01 | 0.06 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 33.33 | 52.22 |
Price Performance
Historical ComparisonAbout CCII Cohen Circle Acquisition Corp. II Class A Ordinary Shares
Cohen Circle Acquisition Corp II is a blank check company.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.